You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Express Scripts
Harvard Business School
Medtronic
Johnson and Johnson

Last Updated: November 29, 2020

DrugPatentWatch Database Preview

Details for Patent: 6,149,940

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,149,940
Title: Tablet with controlled release of alfuzosine chlorhydrate
Abstract:Pharmaceutical tablet which consists of: a) a first layer having the property of swelling considerably and quickly on contact with aqueous biological fluids, the first layer being produced by compression of a mixture or of a granulate comprising hydrophilic polymers, and b) a second layer adjacent to the first layer being formulated with hydrophilic polymers and with other auxiliary substances in order to give the preparation suitable properties of compressibility and in order to allow the release of alfuzosin hydrochloride within a predetermined time period.
Inventor(s): Maggi; Lauretta (Pavia, IT), Conte; Ubaldo (Busto Arisizio., IT), Grenier; Pascal (Saint Louis, FR), Vergnault; Guy (Saint Louis, FR), Dufour; Alain (Paris, FR), Jarreau; Fran.cedilla.ois Xavier (Versailles, FR), Rauch-Desanti; Clemence (Ozoire la Ferriere, FR)
Assignee: Synthelabo (Le Plessis-Robinson, FR) Jagotec AB (Hergiswil, CH)
Application Number:09/147,581
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition;

Drugs Protected by US Patent 6,149,940

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,149,940

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France96 10551Aug 29, 1996
France97 04386Apr 10, 1997
PCT Information
PCT FiledAugust 22, 1997PCT Application Number:PCT/FR97/01515
PCT Publication Date:March 05, 1998PCT Publication Number: WO98/08515

International Family Members for US Patent 6,149,940

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1107   Start Trial
African Regional IP Organization (ARIPO) 9901470   Start Trial
Argentina 009312   Start Trial
Austria 200864   Start Trial
Australia 4020197   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Baxter
Mallinckrodt
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.